Search

Your search keyword '"Summers, Yvonne"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Summers, Yvonne" Remove constraint Author: "Summers, Yvonne"
213 results on '"Summers, Yvonne"'

Search Results

1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

2. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

3. The evolution of non-small cell lung cancer metastases in TRACERx

4. The evolution of lung cancer and impact of subclonal selection in TRACERx

5. Defining the road map to a UK national lung cancer screening programme

6. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

7. Seasonal patterns in immunotherapy outcomes.

11. 94 Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with METexon 14 skipping mutation

12. 84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

13. 190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy

14. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

16. The National Lung Matrix Trial of personalized therapy in lung cancer

17. Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care.

18. 1011: Thoracic radiotherapy and PCI in extensive stage small cell lung cancer following chemoimmunotherapy

21. A regional clinical audit of the Greater Manchester NSCLC reflex testing protocol and genomic testing pathway: examining the downstream effects

22. Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer

23. The routine clinical use of electronic patient-reported outcome measures (ePROMs) for patients with lung cancer

24. Evaluating a new, standardised regional referral proforma for new diagnoses of small cell lung cancer in Greater Manchester

25. A regional clinical audit of the provision of adjuvant systemic anti-cancer treatment following lung cancer resection in eligible patients across Greater Manchester to support national benchmarking

26. Surgical decompression of malignant spinal cord compression (MSCC) in lung cancer: the Manchester experience

27. Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC)

28. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

29. Body composition and lung cancer-associated cachexia in TRACERx

30. The evolution of lung cancer and impact of subclonal selection in TRACERx

31. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

32. MARS 2: Extended Pleurectomy Decortication and Chemotherapy for Pleural Mesothelioma

33. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

35. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

38. Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients

39. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

42. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

43. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

45. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

46. Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

48. An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

49. Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.

50. Developing and testing a web‐based intervention to encourage early help‐seeking in people with symptoms associated with lung cancer

Catalog

Books, media, physical & digital resources